Here are four interesting insights from the report:
• Amid inflation, talent shortages and other disruption, savvy biotech’s are focusing on the fundamentals of preserving cash and producing strong data and evidence to showcase their overall resilience to potential investors.
• In light of the recently passed Inflation Reduction Act and its impact on drug pricing, inflationary rebates and Medicare Part D redesign, biotech leaders need to take a strategic approach around commercialization, launch sequencing and other areas.
• In today’s operating environment, leveraging digital capabilities is essential to activate omnichannel strategies and drive the consistent messaging and personalized customer experience needed to enhance retention and long-term value.
• Given their smaller budgets, evolving regulations and other back-office challenges, many biotech’s are seeking third-party support to create leaner, more efficient tax and finance functions.